S
Sergio Abrignani
Researcher at University of Milan
Publications - 228
Citations - 16532
Sergio Abrignani is an academic researcher from University of Milan. The author has contributed to research in topics: Immune system & Cytotoxic T cell. The author has an hindex of 63, co-authored 206 publications receiving 15038 citations. Previous affiliations of Sergio Abrignani include John Radcliffe Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Binding of Hepatitis C Virus to CD81
Piero Pileri,Yasushi Uematsu,Susanna Campagnoli,Giuliano Galli,Fabiana Falugi,Roberto Petracca,Amy J. Weiner,Michael Houghton,Domenico Rosa,Guido Grandi,Sergio Abrignani +10 more
TL;DR: Recombinant molecules containing this loop bound HCV and antibodies that neutralize HCV infection in vivo inhibited virus binding to CD81 in vitro.
Journal ArticleDOI
SARS — beginning to understand a new virus
Konrad Stadler,Vega Masignani,Markus Eickmann,Stephan Becker,Sergio Abrignani,Hans-Dieter Klenk,Rino Rappuoli +6 more
TL;DR: The genomics of the Sars coronavirus (SARS-CoV), its phylogeny, antigenic structure, immune response and potential therapeutic interventions should the SARS epidemic flare up again are reviewed.
Journal ArticleDOI
Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein
Stefania Crotta,Annalisa Stilla,Andreas Wack,Annalisa D'Andrea,Sandra Nuti,Ugo D'Oro,Marta Mosca,Franco Filliponi,R. Maurizia Brunetto,Ferruccio Bonino,Sergio Abrignani,Nicholas Valiante +11 more
TL;DR: It is reported that ligation of an HCV receptor (CD81) inhibits natural killer (NK) cells, implicate HCV-E2–mediated inhibition of NK cells as an efficient HCV evasion strategy targeting the early antiviral activities ofNK cells and allowing the virus to establish itself as a chronic infection.
Journal ArticleDOI
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
Marco De Simone,Alberto Arrigoni,Grazisa Rossetti,Paola Gruarin,Valeria Ranzani,Claudia Politano,Raoul J. P. Bonnal,Elena Provasi,Maria Lucia Sarnicola,Ilaria Panzeri,Monica Moro,Mariacristina Crosti,Saveria Mazzara,Valentina Vaira,Silvano Bosari,Alessandro Palleschi,Luigi Santambrogio,Giorgio Bovo,Nicola Zucchini,M. Totis,Luca Gianotti,Giancarlo Cesana,Roberto A. Perego,Nirvana Maroni,Andrea Pisani Ceretti,Enrico Opocher,Raffaele De Francesco,Jens Geginat,Hendrik G. Stunnenberg,Sergio Abrignani,Massimiliano Pagani +30 more
TL;DR: In conclusion, high expression in whole-tumor samples of Treg cell signature genes, such as LAYN, MAGEH1, or CCR8, correlated with poor prognosis and are defined as potential targets for tumor immunotherapy.
Journal ArticleDOI
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
Domenico Rosa,Susanna Campagnoli,Carlo Moretto,Eric Guenzi,Lawrence S. Cousens,Michael Chin,Christine Dong,Amy J. Weiner,Lau Johnson Yiu-Nam,Qui-Lim Choo,David Y. Chien,Piero Pileri,Michael Houghton,Sergio Abrignani +13 more
TL;DR: An assay to assess specific binding of recombinant envelope proteins to human cells and neutralization of E2 derived from the HCV-1 genotype was equally distributed among sera from patients infected with HCV genotypes 1, 2, and 3, demonstrating that binding of E 2 is partly independent of E1 hypervariable regions.